Metsera (NASDAQ:MTSR) Shares Up 7.6% – What’s Next?

Metsera, Inc. (NASDAQ:MTSR)’s share price traded up 7.6% during mid-day trading on Monday . The company traded as high as $28.28 and last traded at $27.12. 40,441 shares traded hands during mid-day trading, a decline of 93% from the average session volume of 557,944 shares. The stock had previously closed at $25.21.

Analyst Ratings Changes

Several research analysts recently weighed in on MTSR shares. Guggenheim started coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective on the stock. Evercore ISI assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They set an “outperform” rating for the company. Cantor Fitzgerald initiated coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company. Finally, Bank of America began coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price objective on the stock.

Metsera Trading Up 6.9 %

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.